36:
171:
many people take daily, also since it is mitigated by the controlling factor of their perception of their individual ability to manage the risk-creating situation. When individuals are exposed to involuntary risk (a risk over which they have no control), they make
176:
their primary goal. Under these circumstances, individuals require the probability of risk to be as much as one thousand times smaller than for the same situation under their perceived control (a notable example being the common bias in the perception of
223:
For research that involves more than minimal risk of harm to the subjects, the investigator must assure that the amount of benefit clearly outweighs the amount of risk. Only if there is a favorable risk–benefit ratio may a study be considered
167:
Analyzing a risk can be heavily dependent on the human factor. A certain level of risk in our lives is accepted as necessary to achieve certain benefits. For example,
371:
296:
243:
cannot be done legitimately unless the importance of the objective is in proportion to the risk to the subject. The
Helsinki Declaration and
100:
244:
72:
663:
659:
79:
709:
667:
655:
53:
364:
86:
830:
746:
611:
581:
68:
17:
357:
119:
868:
321:
World
Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects
178:
675:
895:
713:
435:
57:
861:
546:
840:
900:
804:
776:
705:
459:
276:
93:
854:
530:
173:
649:
261:
236:
587:
535:
415:
161:
300:
633:
503:
481:
450:
425:
408:
232:
46:
890:
621:
542:
625:
512:
420:
384:
320:
349:
202:, as determined by currently available data, as measured actuarially for insurance premiums.
591:
8:
498:
430:
240:
751:
701:
516:
445:
403:
825:
789:
756:
681:
603:
380:
256:
168:
599:
520:
474:
469:
794:
617:
572:
820:
741:
693:
486:
398:
266:
884:
799:
766:
761:
271:
208:, as analytically based on system models structured from historical studies.
641:
525:
196:, as disclosed by the fully matured future circumstances when they develop.
835:
689:
562:
552:
637:
629:
595:
557:
464:
697:
685:
332:
35:
731:
157:
736:
225:
379:
141:
145:
27:
Analysis of the risks and potential benefits of an action
60:. Unsourced material may be challenged and removed.
882:
164:the risk and benefits and hence their ratio.
365:
372:
358:
120:Learn how and when to remove this message
664:Preventable fraction among the unexposed
660:Attributable fraction for the population
148:of an action to its potential benefits.
668:Preventable fraction for the population
656:Attributable fraction among the exposed
247:stress a favorable risk–benefit ratio.
14:
883:
353:
214:, as intuitively seen by individuals.
831:Correlation does not imply causation
747:Animal testing on non-human primates
58:adding citations to reliable sources
29:
218:
189:Evaluations of future risk can be:
24:
299:. Capita.wustl.edu. Archived from
25:
912:
34:
169:driving an automobile is a risk
45:needs additional citations for
714:Pre- and post-test probability
436:Patient and public involvement
325:
314:
289:
184:
13:
1:
282:
841:Sex as a biological variable
7:
805:Intention-to-treat analysis
777:Analysis of clinical trials
706:Specificity and sensitivity
460:Randomized controlled trial
277:Reference class forecasting
250:
10:
917:
849:
814:Interpretation of results
813:
775:
724:
674:
648:
610:
580:
571:
547:Nested case–control study
497:
444:
391:
237:World Medical Association
416:Academic clinical trials
634:Relative risk reduction
482:Adaptive clinical trial
426:Evidence-based medicine
409:Adaptive clinical trial
335:. Consort-statement.org
297:"Risk-Benefit Analysis"
233:Declaration of Helsinki
622:Number needed to treat
896:Ethics and statistics
626:Number needed to harm
513:Cross-sectional study
465:Scientific experiment
421:Clinical study design
262:Cost–benefit analysis
245:the CONSORT Statement
154:benefit-risk analysis
150:Risk–benefit analysis
592:Cumulative incidence
69:"Risk–benefit ratio"
54:improve this article
499:Observational study
431:Real world evidence
385:experimental design
241:biomedical research
901:Medical statistics
785:Risk–benefit ratio
752:First-in-man study
702:Case fatality rate
543:Case–control study
517:Longitudinal study
138:benefit-risk ratio
134:risk–benefit ratio
18:Risk/benefit ratio
878:
877:
826:Survivorship bias
790:Systematic review
757:Multicenter trial
720:
719:
710:Likelihood-ratios
682:Clinical endpoint
650:Population impact
604:Period prevalence
381:Clinical research
257:Benefit shortfall
235:, adopted by the
130:
129:
122:
104:
16:(Redirected from
908:
725:Trial/test types
600:Point prevalence
578:
577:
521:Ecological study
504:EBM II-2 to II-3
475:Open-label trial
470:Blind experiment
446:Controlled study
374:
367:
360:
351:
350:
344:
343:
341:
340:
329:
323:
318:
312:
311:
309:
308:
293:
219:Medical research
200:Statistical risk
194:Real future risk
125:
118:
114:
111:
105:
103:
62:
38:
30:
21:
916:
915:
911:
910:
909:
907:
906:
905:
881:
880:
879:
874:
845:
809:
771:
716:
670:
644:
618:Risk difference
606:
567:
501:
493:
448:
440:
404:Trial protocols
387:
378:
348:
347:
338:
336:
331:
330:
326:
319:
315:
306:
304:
295:
294:
290:
285:
253:
221:
187:
126:
115:
109:
106:
63:
61:
51:
39:
28:
23:
22:
15:
12:
11:
5:
914:
904:
903:
898:
893:
876:
875:
873:
872:
869:List of topics
865:
858:
850:
847:
846:
844:
843:
838:
833:
828:
823:
821:Selection bias
817:
815:
811:
810:
808:
807:
802:
797:
792:
787:
781:
779:
773:
772:
770:
769:
764:
759:
754:
749:
744:
742:Animal testing
739:
734:
728:
726:
722:
721:
718:
717:
694:Mortality rate
680:
678:
672:
671:
654:
652:
646:
645:
616:
614:
608:
607:
586:
584:
575:
569:
568:
566:
565:
560:
555:
550:
540:
539:
538:
533:
523:
509:
507:
495:
494:
492:
491:
490:
489:
487:Platform trial
479:
478:
477:
472:
467:
456:
454:
442:
441:
439:
438:
433:
428:
423:
418:
413:
412:
411:
406:
399:Clinical trial
395:
393:
389:
388:
377:
376:
369:
362:
354:
346:
345:
324:
313:
287:
286:
284:
281:
280:
279:
274:
269:
267:Odds algorithm
264:
259:
252:
249:
239:, states that
220:
217:
216:
215:
212:Perceived risk
209:
206:Projected risk
203:
197:
186:
183:
181:vs. driving).
179:risk in flying
160:that seeks to
128:
127:
42:
40:
33:
26:
9:
6:
4:
3:
2:
913:
902:
899:
897:
894:
892:
891:Risk analysis
889:
888:
886:
871:
870:
866:
864:
863:
859:
857:
856:
852:
851:
848:
842:
839:
837:
834:
832:
829:
827:
824:
822:
819:
818:
816:
812:
806:
803:
801:
800:Meta-analysis
798:
796:
793:
791:
788:
786:
783:
782:
780:
778:
774:
768:
767:Vaccine trial
765:
763:
762:Seeding trial
760:
758:
755:
753:
750:
748:
745:
743:
740:
738:
735:
733:
730:
729:
727:
723:
715:
711:
707:
703:
699:
695:
691:
687:
683:
679:
677:
673:
669:
665:
661:
657:
653:
651:
647:
643:
639:
635:
631:
627:
623:
619:
615:
613:
609:
605:
601:
597:
593:
589:
585:
583:
579:
576:
574:
570:
564:
561:
559:
556:
554:
551:
548:
544:
541:
537:
534:
532:
531:Retrospective
529:
528:
527:
524:
522:
518:
514:
511:
510:
508:
505:
500:
496:
488:
485:
484:
483:
480:
476:
473:
471:
468:
466:
463:
462:
461:
458:
457:
455:
452:
451:EBM I to II-1
447:
443:
437:
434:
432:
429:
427:
424:
422:
419:
417:
414:
410:
407:
405:
402:
401:
400:
397:
396:
394:
390:
386:
382:
375:
370:
368:
363:
361:
356:
355:
352:
334:
328:
322:
317:
303:on 2013-10-29
302:
298:
292:
288:
278:
275:
273:
272:Optimism bias
270:
268:
265:
263:
260:
258:
255:
254:
248:
246:
242:
238:
234:
229:
227:
213:
210:
207:
204:
201:
198:
195:
192:
191:
190:
182:
180:
175:
174:risk aversion
170:
165:
163:
159:
155:
151:
147:
143:
139:
135:
124:
121:
113:
102:
99:
95:
92:
88:
85:
81:
78:
74:
71: –
70:
66:
65:Find sources:
59:
55:
49:
48:
43:This article
41:
37:
32:
31:
19:
867:
860:
853:
784:
642:Hazard ratio
526:Cohort study
337:. Retrieved
327:
316:
305:. Retrieved
301:the original
291:
230:
222:
211:
205:
199:
193:
188:
166:
153:
149:
137:
133:
131:
116:
107:
97:
90:
83:
76:
64:
52:Please help
47:verification
44:
836:Null result
795:Replication
690:Infectivity
612:Association
563:Case report
553:Case series
536:Prospective
185:Evaluations
885:Categories
638:Odds ratio
630:Risk ratio
596:Prevalence
582:Occurrence
558:Case study
339:2013-10-25
307:2013-10-25
283:References
80:newspapers
698:Morbidity
686:Virulence
588:Incidence
333:"Consort"
140:) is the
862:Glossary
855:Category
732:In vitro
573:Measures
392:Overview
251:See also
162:quantify
158:analysis
110:May 2012
737:In vivo
226:ethical
144:of the
94:scholar
96:
89:
82:
75:
67:
676:Other
156:) is
142:ratio
101:JSTOR
87:books
515:vs.
383:and
231:The
152:(or
146:risk
136:(or
73:news
228:.
56:by
887::
712:,
708:,
704:,
700:,
696:,
692:,
688:,
684:,
666:,
662:,
658:,
640:,
636:,
632:,
628:,
624:,
620:,
602:,
598:,
594:,
590:,
519:,
132:A
549:)
545:(
506:)
502:(
453:)
449:(
373:e
366:t
359:v
342:.
310:.
123:)
117:(
112:)
108:(
98:·
91:·
84:·
77:·
50:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
